Edoxaban: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Edoxaban: clinical details
Prescribing considerations
- Confirm the licensed indication and assess thromboembolic risk against bleeding risk.
- Calculate creatinine clearance using Cockcroft–Gault; renal function, body weight and interacting P-glycoprotein inhibitors affect product-specific prescribing.
- Review haemostasis-affecting medicines and strong P-glycoprotein inhibitors or inducers.
- Edoxaban is not recommended for mechanical heart valves, early after bioprosthetic valve implantation, moderate-to-severe mitral stenosis, haemodynamically unstable pulmonary embolism, or thrombotic antiphospholipid syndrome.
- Plan interruptions and transitions between anticoagulants carefully.
Contraindications and cautions
- Clinically significant active bleeding.
- A lesion or condition carrying a significant risk of major bleeding.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
- Uncontrolled severe hypertension.
- Concurrent anticoagulant treatment, except in specified switching or catheter-maintenance circumstances.
- Pregnancy or breastfeeding.
- Hypersensitivity to edoxaban or an excipient.
Monitoring
- Before treatment, assess full blood count, creatinine clearance, liver function, body weight and baseline clotting tests.
- Review adherence, bleeding, anaemia, thrombosis, renal or hepatic change and interacting medicines during treatment.
- Repeat full blood count, liver function and renal assessment periodically, with closer review when older, frail, renally impaired or acutely unwell.
- Routine INR, PT or aPTT monitoring does not reliably quantify edoxaban’s effect; a calibrated anti-factor Xa assay may assist in selected emergencies.
Clinical pharmacology
Edoxaban is a selective, direct and reversible factor Xa inhibitor. It is a P-glycoprotein substrate, is only weakly metabolised through CYP3A4/5, has mixed renal and non-renal clearance, and has an approximate terminal half-life of 10–14 hours.
Formulation and product differences
- Lixiana products are film-coated tablets.
- The tablets may be crushed and mixed with water or apple puree; licensed nasogastric or gastric-tube administration is also described.
- Tablet appearance differs by strength, so verify strength from the packaging rather than colour alone.
Edoxaban interactions
Ask a pharmacist or prescriber before starting, stopping or changing any prescription, non-prescription or herbal medicine.
Other anticoagulants
The combination substantially increases bleeding risk and is contraindicated except in defined switching or specialist-managed circumstances.
Aspirin and antiplatelets such as clopidogrel
These can increase clinically important bleeding and require a clear clinical indication and review.
NSAIDs such as ibuprofen or naproxen
These increase bleeding risk. Chronic use is not recommended; check before non-prescription use.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.